Proinflammatory circulating markers: new players for evaluating asymptomatic acute cardiovascular toxicity in breast cancer treatment

Micheletti, P. L.; Silva, Janaína Carla da; Scandolara, Thalita Basso; Kern, Rodrigo; Alves, Vinícius Dias; Malanowski, Jessica; Victorino, Vanessa Jacob; Herrera, Ana Cristina; Rech, Daniel; Souza, Juliana Alves; Simão, A. N. C.; Dichi, Isaías

doi:10.1080/1120009x.2021.1873632

Cited by 6 publications

(9 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…C-reactive protein (CRP), an inflammatory marker, has been assessed as a biomarker for the detection of CTRCD. Previous studies were identified in this review to show higher or lower levels of CRP in response to chemotherapy in breast cancer patients [ 92 , 163 , 286 , 295 ] with no clear association with the onset of CTRCD. Other studies found no association between the levels of CRP and subsequent cardiotoxicity [ 105 ].…”

Section: Resultsmentioning

confidence: 86%

“…Another prospective study showed elevation of the levels of pro-inflammatory markers, free iron (Fe), tumor necrosis factor alpha (TNF-α) and homocysteine were elevated in breast cancer patients treated with doxorubicin (DOX; n = 33), paclitaxel (PTX; n = 35) or trastuzumab (TZ; n = 52) compared to the healthy controls (n = 50). These levels were accompanied by elevated levels of CK-MB and hs-CRP, indicating that the proinflammatory markers may potentially be used as promising predictive indicators of cancer therapy-induced cardiac injury [ 286 ]. Tromp et al, 2020 [ 153 ], identified a distinct biomarker profile in breast cancer survivors (n = 342), who experienced cardiac dysfunction even a decade post-treatment with chemotherapy compared to the control group (n = 346).…”

Section: Resultsmentioning

confidence: 99%

“…In addition to above-mentioned biomarkers, other potentially promising biomarkers are currently under investigation for their utility in the detection and/or prediction of CTRCD including: coronary artery calcification [ 298 ], endothelin-1 [ 299 ], neuregulin-1 [ 285 , 300 ], plasma bioactive adrenomedullin (ADM) [ 301 ], fragmented QRS (fQRS) [ 302 ], D-dimer [ 303 ], soluble fms-like tyrosine kinase receptor (sFlt)-1 [ 105 ], soluble ST2 (sST2) [ 145 , 149 , 171 , 279 , 304 ], CK-MB [ 134 , 286 ], topoisomerase II α gene ( TOP2A ) [ 305 ], cardiac myosin light chain 1 (cMLC-1) [ 306 ], vascular endothelial growth factor (VEGF) [ 93 ], placental growth factor (PIGF) [ 93 , 98 ], procollagen-derived type-I C-terminal-propeptide (PICP) [ 307 ], epicardial adipose tissue (EAT) volume [ 308 , 309 ], circulating bilirubin [ 310 ], hemopexin [ 311 ], glycated hemoglobin (HbA(1)c) [ 103 ], advanced oxidation protein products (AOPP) [ 102 ], human resistin [ 312 ] and vascular adhesion molecule 1 (VCAM-1) [ 117 ].…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

New Insights in the Era of Clinical Biomarkers as Potential Predictors of Systemic Therapy-Induced Cardiotoxicity in Women with Breast Cancer: A Systematic Review

Alexandraki

Papageorgiou

Zacharia

et al. 2023

Cancers

View full text Add to dashboard Cite

Cardiotoxicity induced by breast cancer therapies is a potentially serious complication associated with the use of various breast cancer therapies. Prediction and better management of cardiotoxicity in patients receiving chemotherapy is of critical importance. However, the management of cancer therapy-related cardiac dysfunction (CTRCD) lacks clinical evidence and is based on limited clinical studies. Aim: To provide an overview of existing and potentially novel biomarkers that possess a promising predictive value for the early and late onset of CTRCD in the clinical setting. Methods: A systematic review of published studies searching for promising biomarkers for the prediction of CTRCD in patients with breast cancer was undertaken according to PRISMA guidelines. A search strategy was performed using PubMed, Google Scholar, and Scopus for the period 2013–2023. All subjects were >18 years old, diagnosed with breast cancer, and received breast cancer therapies. Results: The most promising biomarkers that can be used for the development of an alternative risk cardiac stratification plan for the prediction and/or early detection of CTRCD in patients with breast cancer were identified. Conclusions: We highlighted the new insights associated with the use of currently available biomarkers as a standard of care for the management of CTRCD and identified potentially novel clinical biomarkers that could be further investigated as promising predictors of CTRCD.

show abstract

Section: Resultsmentioning

confidence: 86%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

New Insights in the Era of Clinical Biomarkers as Potential Predictors of Systemic Therapy-Induced Cardiotoxicity in Women with Breast Cancer: A Systematic Review

Alexandraki

Papageorgiou

Zacharia

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

“…One of the main drugs is paclitaxel, which mainly takes effect by stabilizing microtubules and inhibiting mitosis. However, the side effect of paclitaxel is harm to the cardiovascular system [52,53], which increases the risk of a cardiac accident in patients.…”

Section: Vascular Stentmentioning

confidence: 99%

Diamond-like Carbon Coatings in the Biomedical Field: Properties, Applications and Future Development

Peng

Wang

et al. 2022

Coatings

View full text Add to dashboard Cite

Repairment and replacement of organs and tissues are part of the history of struggle against human diseases, in addition to the research and development (R&D) of drugs. Acquisition and processing of specific substances and physiological signals are very important to understand the effects of pathology and treatment. These depend on the available biomedical materials. The family of diamond-like carbon coatings (DLCs) has been extensively applied in many industrial fields. DLCs have also been demonstrated to be biocompatible, both in vivo and in vitro. In many cases, the performance of biomedical devices can be effectively enhanced by coating them with DLCs, such as vascular stents, prosthetic heart valves and surgical instruments. However, the feasibility of the application of DLC in biomedicine remains under discussion. This review introduces the current state of research and application of DLCs in biomedical devices, their potential application in biosensors and urgent problems to be solved. It will be useful to build a bridge between DLC R&D workers and biomedical workers in order to develop high-performance DLC films/coatings, promote their practical use and develop their potential applications in the biomedical field.

show abstract

“…Michelettie et al, 4 demonstraram a existência de uma rede pró-inflamatória desencadeada pela quimioterapia do câncer de mama que poderia aumentar a permeabilidade dos cardiomiócitos, permitir o extravasamento de proteínas circulantes e induzir a produção de um marcador inflamatório como a Proteína C Reativa altamente sensível, o que evidencia o papel potencial dos biomarcadores na identificação do TCIA. 4 …”

unclassified

Biomarcadores na Avaliação de Pacientes Submetidos à Quimioterapia com Antraciclinas

Issa

2023

Arquivos Brasileiros De Cardiologia

View full text Add to dashboard Cite

Proinflammatory circulating markers: new players for evaluating asymptomatic acute cardiovascular toxicity in breast cancer treatment

Cited by 6 publications

References 74 publications

New Insights in the Era of Clinical Biomarkers as Potential Predictors of Systemic Therapy-Induced Cardiotoxicity in Women with Breast Cancer: A Systematic Review

New Insights in the Era of Clinical Biomarkers as Potential Predictors of Systemic Therapy-Induced Cardiotoxicity in Women with Breast Cancer: A Systematic Review

Diamond-like Carbon Coatings in the Biomedical Field: Properties, Applications and Future Development

Biomarcadores na Avaliação de Pacientes Submetidos à Quimioterapia com Antraciclinas

Contact Info

Product

Resources

About